Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.47 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.47 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.47 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15107851 | 1.00 | HPGD (0.62) | HPGDEPHX1RECQLUSP2SMN1; SMN2 | |
| SCHEMBL1096914 | 1.00 | HPGD (0.62) | HPGDEPHX1RECQLUSP2SMN1; SMN2 | |
| SCHEMBL23946114 | 0.96 | HPGD (0.61) | HPGDEPHX1RECQLUSP2SMN1; SMN2 | |
| SCHEMBL19852527 | 0.93 | HPGD (0.62) | HPGDEPHX1RECQLUSP2SMN1; SMN2 | |
| SCHEMBL47319 | 0.93 | HPGD (0.60) | HPGDEPHX1RECQLUSP2SMN1; SMN2 | |
| Ethane SCHEMBL897978 | 0.93 | HPGD (0.60) | HPGDEPHX1RECQLUSP2SMN1; SMN2 | |
| SCHEMBL21183487 | 0.91 | HPGD (0.64) | HPGDEPHX1RECQLUSP2SMN1; SMN2 | |
| SCHEMBL1148424 | 0.91 | HPGD (0.58) | HPGDEPHX1RECQLUSP2SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL6803311 | 0.91 | HPGD (0.58) | HPGDEPHX1RECQLUSP2SMN1; SMN2 | |
| Methane SCHEMBL28191135 | 0.91 | HPGD (0.58) | HPGDEPHX1RECQLUSP2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001880-A1 | Bicyclic DGK Inhibitors | INCYTE CORPORATION | 2026-01-01 | — | — | US | disclosed |
| WO-2024168004-A1 | BIARYL AMIDE-CONTAINING AGONISTS OF OREXIN RECEPTOR TYPE 2 | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-08-15 | — | — | WO | disclosed |
| US-20240083900-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2024-03-14 | — | — | US | disclosed |
| EP-4244223-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | Biogen MA Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-116783199-A | Pyrazolo [1,5-A ] pyrazine derivatives as BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| WO-2022104079-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BIOGEN MA INC. (US) | 2022-05-19 | — | — | WO | disclosed |
| US-20130274475-A1 | BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME (US) | 2013-10-17 | — | — | US | disclosed |
| US-8487093-B2 | β-lactamase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20110294777-A1 | BETA-LACTAMASE INHIBITORS | MERCK SHARP & DOHME CORP. | 2011-12-01 | — | — | US | disclosed |
| WO-2009091856-A2 | BETA-LACTAMASE INHIBITORS | MERCK & CO., INC. (US) | 2009-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110294777-A1 | BETA-LACTAMASE INHIBITORS | MGAM, RPIA, LBR | HPGD 813/4885EPHX1 3302/4885RECQL 406/4885 |
| US-20130274475-A1 | BETA-LACTAMASE INHIBITORS | MGAM, RPIA, XDH | HPGD 731/4885EPHX1 3442/4885RECQL 424/4885 |
| US-20240083900-A1 | PYRAZOLO[1,5-A]PYRAZINE DERIVATIVES AS BTK INHIBITORS | BTK, SYK, LYN | HPGD 3256/4885EPHX1 3668/4885RECQL 2653/4885 |
| US-20260001880-A1 | Bicyclic DGK Inhibitors | DGKA, DGKG, DGKZ | HPGD 4183/4885EPHX1 2050/4885RECQL 2059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.